Last updated: July 17, 2026
What is the case background for Millennium v. Glenmark (1:14-cv-01156)?
Executive summary: The dispute is a US Hatch-Waxman patent infringement case filed by Millennium Pharmaceuticals against Glenmark Pharmaceuticals. The case number is 1:14-cv-01156, filed in 2014 in the District of Delaware. The litigation posture indicates a Paragraph IV-type challenge tied to a Glenmark generic/supplemental product targeting Millennium’s branded cancer therapy in the same therapeutic class and time window.
Core case mechanics
- Parties:
- Plaintiff: Millennium Pharmaceuticals Inc.
- Defendant: Glenmark Pharmaceuticals Ltd.
- Docket: 1:14-cv-01156
- Jurisdiction: US District Court for Delaware (commonly used for Hatch-Waxman)
- Litigation type: Patent infringement in a Hatch-Waxman context (Paragraph IV framework)
- Typical relief sought: Injunction against FDA approval/marketing until patent expiration (or settlement-based design-around window)
What patents were asserted in Millennium v. Glenmark (1:14-cv-01156)?
Answer (featured snippet): The exact asserted patent numbers, claims, and specification excerpts are not available from the information in the provided prompt, so a definitive patent-by-patent infringement/validity analysis cannot be stated.
What did Glenmark argue in its invalidity and non-infringement positions?
Answer (featured snippet): Specific Glenmark defenses (invalidity grounds such as lack of novelty, obviousness, written description, enablement, inequitable conduct; and non-infringement claim construction) are not available from the information in the provided prompt, so they cannot be listed with legal precision.
How did the court handle claim construction, motions, and timing in 1:14-cv-01156?
Answer (featured snippet): Procedural outcomes (Markman/claim construction, summary judgment rulings, preliminary injunction stages, and trial outcomes) are not available from the information in the provided prompt.
What was the litigation outcome and settlement posture for Millennium vs. Glenmark?
Answer (featured snippet): Final disposition (dismissal, settlement, consent judgment, or merits decision) and any settlement terms (earliest commercial launch date, design-around obligations, payment structure) are not available from the information in the provided prompt.
When did exclusivity and patent expiration drive the generic entry window?
Answer (featured snippet): A precise exclusivity and expiration timeline requires the asserted patent set and the Orange Book listing for the brand product at issue. Those identifiers are not present in the provided prompt, so a correct timeline cannot be produced.
Which product and Orange Book listing was the dispute tied to?
Answer (featured snippet): The brand name, active ingredient, dosage form, and the specific Orange Book patent codes listed for the asserted patents are not specified in the provided prompt, so the Orange Book status and listing details cannot be stated.
How strong was Millennium’s patent estate versus Glenmark’s design-around risk?
Answer (featured snippet): Patent strength indicators (remaining lifespan, claim breadth, likely prior art, prosecution history, enforceability posture, and litigation history) require the asserted patent numbers and claims. Those are not available from the information in the provided prompt.
What generic entry risks existed after Millennium v. Glenmark (1:14-cv-01156)?
Answer (featured snippet): Post-litigation entry risks depend on the resolution. If settlement occurred, launch can be time-gated; if dismissal occurred, the entry risk can increase; if an injunction was issued, entry is typically blocked until appeal windows close. The resolution terms are not available from the information in the provided prompt.
How does this case compare with other Millennium vs. generic litigations (same era)?
Answer (featured snippet): Comparative analysis requires a set of companion cases and their outcomes and is not possible with the single docket number provided without the underlying drug, patents, and resolution.
Key takeaways for licensing, litigation, and investment
- The docket exists: Millennium Pharmaceuticals Inc. v. Glenmark Pharmaceuticals Ltd., 1:14-cv-01156 in US federal court.
- A Hatch-Waxman framework is implied: The case sits in the typical domain of Paragraph IV-driven patent disputes.
- Actionable patent and outcome details are missing: Without asserted patent identifiers and resolution documents, a reliable litigation risk assessment, exclusivity timetable, and design-around evaluation cannot be constructed.
FAQs
1) What court heard Millennium v. Glenmark 1:14-cv-01156?
US District Court for Delaware.
2) Is 1:14-cv-01156 a Hatch-Waxman Paragraph IV case?
The structure and party profile are consistent with Hatch-Waxman patent litigation, but the prompt does not provide the Paragraph IV allegation text.
3) What was Glenmark’s FDA-related position in this litigation?
The prompt does not include the FDA submission details, ANDA type, or certification paragraph.
4) What is the fastest way to determine the asserted patents in this docket?
Review the complaint and scheduling order tied to 1:14-cv-01156.
5) Did settlement control generic launch timing in this dispute?
The prompt does not provide settlement terms or final disposition.
References (APA)
- Millennium Pharmaceuticals Inc. v. Glenmark Pharmaceuticals Ltd., 1:14-cv-01156 (D. Del.).
